cardiovascular-agents and andrographolide

cardiovascular-agents has been researched along with andrographolide* in 1 studies

Other Studies

1 other study(ies) available for cardiovascular-agents and andrographolide

ArticleYear
Andrographolide mitigates cardiac apoptosis to provide cardio-protection in high-fat-diet-induced obese mice.
    Environmental toxicology, 2020, Volume: 35, Issue:6

    Excessive intake of high fat diet (HFD) and associated obese conditions are critical contributors of cardiac diseases. In this study, an active metabolite andrographolide from Andrographis paniculata was found to ameliorate HFD-induced cardiac apoptosis. C57/BL6 mouse were grouped as control (n = 9), obese (n = 8), low dose (25 mg/kg/d) andrographolide treatment (n = 9), and high dose (50 mg/kg/d) andrographolide treatment (n = 9). The control group was provided with standard laboratory chow and the other groups were fed with HFD. Andrographolide was administered through oral gavage for 1 week. Histopathological analysis showed increase in apoptotic nuclei and considerable cardiac-damages in the obese group signifying cardiac remodeling effects. Further, Western blot results showed increase in pro-apoptotic proteins and decrease in the proteins of IGF-1R-survival signaling. However, feeding of andrographolide significantly reduced the cardiac effects of HFD. The results strongly suggest that andrographolide supplementation can be used for prevention and treatment of cardiovascular disease in obese patients.

    Topics: Andrographis; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cardiovascular Agents; Diet, High-Fat; Diterpenes; Heart; Male; Mice; Mice, Obese; Myocardium; Obesity; Signal Transduction

2020